Nephron-sparing surgery for renal tumours on kidney transplantation
Autor: | S. Martínez Breijo, L. Álvarez Castelo, F. Gómez Veiga, J. Ponce Díaz-Reixa, M. González Martín, D. López García, V. Chantada Abal |
---|---|
Rok vydání: | 2010 |
Předmět: |
medicine.medical_specialty
education.field_of_study business.industry medicine.medical_treatment Population Urology Renal function Retrospective cohort study Histology General Medicine urologic and male genital diseases medicine.disease Nephrectomy Surgery Transplantation Medicine Radical surgery business education Kidney transplantation |
Zdroj: | Actas Urológicas Españolas (English Edition). 34:811-814 |
ISSN: | 2173-5786 |
Popis: | Introduction Nowadays, nephron-sparing surgery for renal carcinoma achieves good oncological results, similar to radical surgery, with the advantage of preserving renal function. Renal cell carcinomas appear de novo in 4.6% of post-transplant patients compared with 3% of tumors in the general population, affecting less than 10% to renal allograft. Objective The purpose is to analyze our experience and make a literature review about the role of nephron-sparing surgery to treat de novo renal tumours in renal grafts. Material and methods A retrospective and descriptive analysis has been realized, finding four patients who presented with de novo renal tumours over renal graft after kidney transplantation and treated by nephron-sparing surgery. A Medline review is done to search similar series published. Oncological and functional results were reviewed and analyzed. We worked with SPSS 12.0 software. Results Medium age at diagnosis was 46.5 and (42–62). Medium size was 2.4 cm. (1.5–3.5) and final histology showed medium tumours size of 3.0 cm. (1.7–3.5). Medium hospital stay was 6.0 d. Medium time from transplantation to diagnosis was 92 months (42–192). NSS was done in all cases, in 3 cases tumorectomy and one partial nephrectomy. Transfusion was only needed in one case. All cases had pT1aN0M0 RCC histology exam. Renal function did not change from preoperative. All patients are free of progression with a medium follow-up of 46.5 months (15–58). Conclusions NSS could be an option to treat graft tumours in selected cases, preserving renal function. In our experience, it is a safe and efficient treatment in patients with small de novo renal tumours over renal graft. |
Databáze: | OpenAIRE |
Externí odkaz: |